184 related articles for article (PubMed ID: 18025156)
1. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
Tyner JW; Walters DK; Willis SG; Luttropp M; Oost J; Loriaux M; Erickson H; Corbin AS; O'Hare T; Heinrich MC; Deininger MW; Druker BJ
Blood; 2008 Feb; 111(4):2238-45. PubMed ID: 18025156
[TBL] [Abstract][Full Text] [Related]
2. Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; Loriaux M; Goss VL; Lee KA; Eide CA; Wong MJ; Stoffregen EP; McGreevey L; Nardone J; Moore SA; Crispino J; Boggon TJ; Heinrich MC; Deininger MW; Polakiewicz RD; Gilliland DG; Druker BJ
Cancer Cell; 2006 Jul; 10(1):65-75. PubMed ID: 16843266
[TBL] [Abstract][Full Text] [Related]
3. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.
Maxson JE; Abel ML; Wang J; Deng X; Reckel S; Luty SB; Sun H; Gorenstein J; Hughes SB; Bottomly D; Wilmot B; McWeeney SK; Radich J; Hantschel O; Middleton RE; Gray NS; Druker BJ; Tyner JW
Cancer Res; 2016 Jan; 76(1):127-38. PubMed ID: 26677978
[TBL] [Abstract][Full Text] [Related]
4. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells.
Nizard P; Ezan F; Bonnier D; Le Meur N; Langouët S; Baffet G; Arlot-Bonnemains Y; Théret N
BMC Genomics; 2014 Dec; 15(1):1169. PubMed ID: 25540073
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
7. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening.
Supekova L; Supek F; Lee J; Chen S; Gray N; Pezacki JP; Schlapbach A; Schultz PG
J Biol Chem; 2008 Jan; 283(1):29-36. PubMed ID: 17951261
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase as a target in the treatment of hematological malignancies.
Yin B
Leuk Res; 2011 Oct; 35(10):1416-8. PubMed ID: 21592572
[TBL] [Abstract][Full Text] [Related]
9. RNAi screen for rapid therapeutic target identification in leukemia patients.
Tyner JW; Deininger MW; Loriaux MM; Chang BH; Gotlib JR; Willis SG; Erickson H; Kovacsovics T; O'Hare T; Heinrich MC; Druker BJ
Proc Natl Acad Sci U S A; 2009 May; 106(21):8695-700. PubMed ID: 19433805
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
13. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Arora S; Bisanz KM; Peralta LA; Basu GD; Choudhary A; Tibes R; Azorsa DO
Gynecol Oncol; 2010 Sep; 118(3):220-7. PubMed ID: 20722101
[TBL] [Abstract][Full Text] [Related]
14. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
16. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
17. Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
Huang YT; Lee LT; Lee PP; Lin YS; Lee MT
Anticancer Res; 2005; 25(3B):2017-25. PubMed ID: 16158939
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
[TBL] [Abstract][Full Text] [Related]
19. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.
Cioccio J; Claxton D
Expert Opin Investig Drugs; 2019 Apr; 28(4):337-349. PubMed ID: 30775933
[TBL] [Abstract][Full Text] [Related]
20. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
